Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809400 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 14
- Study locations
NCT06809400: Recruiting Phase 1 study of Parkinson Disease, sponsored by Eli Lilly and Company.
NCT06809400 is a Phase 1 study of Parkinson Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 127 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06809400, a Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY4006896
Study Locations (14)
Florida
- K2 Medical Research, LLC - Maitland
- Aqualane Clinical Research - Naples
- Charter Research - Orlando
- Progressive Medical Research - Port Orange
- K2 Medical Research, LLC - The Villages
- Charter Research - The Villages
California
- Collaborative Neuroscience Network - CNS - Los Alamitos
- Collaborative Neuroscience Network - CNS - Los Alamitos
Washington
- Evergreen Health Research - Kirkland
- Inland Northwest Research - Spokane
Other
- P-One Clinic - Hachiōji
- Oita University Hospital - Yufu
Michigan
- QUEST Research Institute - Farmington Hills
Texas
- PPD Development, LP - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT06809400 shows while recruiting
NCT06809400 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06809400 lists 14 locations in 6 states (Florida, California, Washington).
Frequently Asked Questions
What is clinical trial NCT06809400 about?
NCT06809400 is a clinical study titled "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease". The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
What is the current status of trial NCT06809400?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2025-02-18. Estimated completion is 2028-01.
What conditions does trial NCT06809400 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06809400?
The interventions under investigation include: Placebo (DRUG), LY4006896 (DRUG).
Who is sponsoring clinical trial NCT06809400?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809400 being conducted?
This trial has 14 study locations across California, Florida, Michigan, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06809400's enrollment target sits among peer trials
127 66th of 297 higher than 231 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
-
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI